Department of Radiology, Zhongshan Hospital, Shanghai Medical College, Fudan University, Shanghai Institute of Medical Imaging, Shanghai 200032, China.
Department of Radiology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200021, China.
Contrast Media Mol Imaging. 2017 Jun 21;2017:9265098. doi: 10.1155/2017/9265098. eCollection 2017.
We investigated effectiveness of ultrasmall superparamagnetic iron oxide enhanced susceptibility weighted imaging (USPIO-enhanced SWI) and mean vessel density imaging () in monitoring antiangiogenic effects of Sorafenib on orthotopic hepatocellular carcinoma (HCC). Thirty-five HCC xenografts were established. USPIO-enhanced SWI and were performed on a 1.5 T MR scanner at baseline, 7, 14, and 21 days after Sorafenib treatment. Intratumoral susceptibility signal intensity (ITSS) and were serially measured and compared between the treated ( = 15) and control groups ( = 15). Both ITSS and were significantly lower in the treated group at each time point ( < 0.05). Measurements in the treated group showed that ITSS persisted at 7 days ( = 0.669) and increased at 14 and 21 days ( < 0.05), while significantly declined at 7 days ( = 0.028) and gradually increased at 14 and 21 days. In the treated group, significant correlation was found between and histologic microvessel density (MVD) ( = 0.753, 0.001), and ITSS correlated well with MVD ( = 0.742, = 0.002) after excluding the data from baseline. This study demonstrated that USPIO-enhanced SWI and could provide novel biomarkers for evaluating antiangiogenic effects of Sorafenib on HCC.
我们研究了超顺磁氧化铁增强敏感加权成像（USPIO-enhanced SWI）和平均血管密度成像（）在监测索拉非尼对原位肝癌（HCC）抗血管生成作用中的效果。建立了 35 个 HCC 异种移植模型。在索拉非尼治疗前、治疗后 7、14 和 21 天，在 1.5TMR 扫描仪上进行 USPIO-enhanced SWI 和。在每个时间点，治疗组（=15）和对照组（=15）的肿瘤内磁化率信号强度（ITSS）和均进行了连续测量和比较。在每个时间点，治疗组的 ITSS 和均显著降低（<0.05）。治疗组的测量结果表明，ITSS 在第 7 天持续（=0.669），在第 14 和 21 天增加（<0.05），而在第 7 天显著下降（=0.028），并逐渐增加在第 14 和 21 天。在治疗组中，与组织学微血管密度（MVD）之间存在显著相关性（=0.753，=0.001），排除基线数据后，ITSS 与 MVD 相关性良好（=0.742，=0.002）。本研究表明，USPIO-enhanced SWI 和可以为评估索拉非尼对 HCC 的抗血管生成作用提供新的生物标志物。
